Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Operating Leases (2020 - 2025)

Korro Bio's Operating Leases history spans 6 years, with the latest figure at $40.8 million for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases fell 6.13% year-over-year to $40.8 million, compared with a TTM value of $40.8 million through Dec 2025, down 6.13%, and an annual FY2025 reading of $40.8 million, down 6.13% over the prior year.
  • Operating Leases for Q4 2025 was $40.8 million at Korro Bio, down from $41.5 million in the prior quarter.
  • The five-year high for Operating Leases was $45.2 million in Q1 2025, with the low at $209000.0 in Q4 2022.
  • Average Operating Leases over 5 years is $32.4 million, with a median of $30.2 million recorded in 2021.
  • Year-over-year, Operating Leases tumbled 99.28% in 2022 and then surged 14835.89% in 2023.
  • Tracing KRRO's Operating Leases over 5 years: stood at $28.9 million in 2021, then tumbled by 99.28% to $209000.0 in 2022, then surged by 14835.89% to $31.2 million in 2023, then skyrocketed by 39.29% to $43.5 million in 2024, then fell by 6.13% to $40.8 million in 2025.
  • Per Business Quant, the three most recent readings for KRRO's Operating Leases are $40.8 million (Q4 2025), $41.5 million (Q3 2025), and $44.6 million (Q2 2025).